<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1790">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137860</url>
  </required_header>
  <id_info>
    <org_study_id>HGMDI/21/204/03/67</org_study_id>
    <nct_id>NCT05137860</nct_id>
  </id_info>
  <brief_title>Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD</brief_title>
  <official_title>Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive Minimal Residual Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various drugs have been added to different treatment regimens in order to improve the&#xD;
      response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that&#xD;
      adding Bortezomib to the relapsing regimen improves the proportion of second complete&#xD;
      remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can&#xD;
      drastically modify the prognosis of patients, since their synergy with drugs such as steroids&#xD;
      has positioned them as an attractive strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mortality associated with leukemia has decreased due to the use of various chemotherapy&#xD;
      combinations, the addition of new agents, or the chemical modification of existing drugs.&#xD;
      Despite advances in treatment, the prognosis in the adult population continues to be&#xD;
      unfavorable. About 25% of the patients will be refractory to the first treatment regimen and&#xD;
      the rest will have a disease-free survival below 40%. The chemotherapy intensity reduction&#xD;
      strategy based on risk stratification according to Minimal Residual Disease (MRD) is a&#xD;
      strategy used by various pediatric centers in order to detect patients at high risk of&#xD;
      relapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 19, 2021</start_date>
  <completion_date type="Anticipated">June 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical Randomized Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital discharge</measure>
    <time_frame>3 months</time_frame>
    <description>The event in which patient is discharge from Hospital stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of days of hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukocytes count</measure>
    <time_frame>3 months</time_frame>
    <description>Number of leukocytes found in peripheral blood at the end of each chemotherapy cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelets count</measure>
    <time_frame>3 months</time_frame>
    <description>Number of platelets found in peripheral blood at the end of each chemotherapy cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Date of Remission</measure>
    <time_frame>3 month</time_frame>
    <description>Time in which the patient completes remission</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Acute Lymphoblastic Leukemia, in Relapse</condition>
  <condition>Chemotherapeutic Toxicity</condition>
  <condition>Minimal Residual Disease</condition>
  <arm_group>
    <arm_group_label>Standard Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme in combination with Bortezomib for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.</description>
    <arm_group_label>Bortezomib Treatment Group</arm_group_label>
    <other_name>Intervention Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmatory diagnosis of Acute Lymphoblastic Leukemia relapsed to&#xD;
             bone marrow described with more than 5% blasts in bone marrow at any stage of&#xD;
             treatment or positivity of minimal residual disease at any stage of treatment.&#xD;
&#xD;
          -  Patients who have signed their informed consent from the institution for&#xD;
             hospitalization, and accepted the performance of the bone marrow study, and the&#xD;
             administration of chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of phenotypic leukemia or bilinear leukemia&#xD;
&#xD;
          -  Patients treated only with palliative regimen or transfusion support&#xD;
&#xD;
          -  Patients without the administration of prophylaxis to the central nervous system by&#xD;
             intrathecal chemotherapy&#xD;
&#xD;
          -  Patients with lymphoblastic leukemia with a positive Philadelphia chromosome&#xD;
&#xD;
          -  Patients with severe comorbidities may put treatment therapy at risk.&#xD;
&#xD;
          -  Patient with a history of cardiac toxicity or arrhythmias associated with treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adolfo Martinez Tovar, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General de Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian O Ramos Peñafiel, PhD</last_name>
    <phone>+52 55 27892000</phone>
    <phone_ext>2020</phone_ext>
    <email>leukemiachop@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adan G Gallardo Rodriguez, MSc</last_name>
    <phone>+52 55 27892000</phone>
    <phone_ext>2020</phone_ext>
    <email>nutriologo.agallardo8@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4935-9.</citation>
    <PMID>8197160</PMID>
  </reference>
  <results_reference>
    <citation>Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, Coletti V, Gurnari C, Romano M, Cefalo MG, Girardi K, Trevisan V, Bertaina V, Merli P, Locatelli F. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24.</citation>
    <PMID>28116786</PMID>
  </results_reference>
  <results_reference>
    <citation>Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 Jul;186(2):274-285. doi: 10.1111/bjh.15919. Epub 2019 Apr 7.</citation>
    <PMID>30957229</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>Christian Omar Ramos-Peñafiel, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Relapse</keyword>
  <keyword>Minimal Residual Disease</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All participants and their information will be managed by intern investigators and will be kept secure for personal data protection according to Mexican laws.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

